Apr 5 |
Candel (CADL) Up on Upbeat Data From Pancreatic Cancer Study
|
Apr 5 |
Ford, Candel Therapeutics, Nvidia, Palantir, Tesla: Why These 5 Stocks Are On Investors' Radars Today
|
Apr 4 |
After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study
|
Apr 4 |
Candel stock soars on positive data from mid-stage pancreatic cancer drug trial
|
Apr 4 |
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
|
Mar 28 |
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
|
Mar 28 |
Candel Therapeutics GAAP EPS of -$0.38
|
Mar 28 |
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
|